Pemvidutide Tracker
Track the Muscle-Preserving GLP-1/Glucagon Dual Agonist
Pemvidutide (ALT-801) combines GLP-1 and glucagon agonism for weight loss that may better preserve lean muscle mass. Track weekly injections, body composition, and progress with Shotlee during Phase 3 trials.
What is Pemvidutide?
Pemvidutide is Altimmune's once-weekly subcutaneous injection that activates both GLP-1 and glucagon receptors simultaneously. While GLP-1 agonism reduces appetite and slows gastric emptying, the glucagon component increases resting energy expenditure and promotes fat oxidation through completely different pathways.
The MOMENTUM Phase 2 trial demonstrated 10–16% weight loss with meaningful preservation of lean body mass compared to other GLP-1 drugs. This muscle-preservation angle is clinically significant — one of the major concerns with current GLP-1 medications is that 25–40% of weight lost is lean mass, not fat.
Altimmune has completed its End-of-Phase 2 meeting with the FDA and agreed on a Phase 3 registration program. If successful, pemvidutide could be approved as a differentiated option for patients prioritizing body composition over pure scale weight.
FAQ
What is pemvidutide?
A weekly GLP-1/glucagon dual agonist from Altimmune in Phase 3 trials. Phase 2 showed 10–16% weight loss with better lean mass preservation than standard GLP-1 drugs.
Why does the glucagon component matter?
Glucagon increases energy expenditure and fat burning, potentially preserving more lean muscle during weight loss. This addresses the major concern about muscle loss on GLP-1 medications.
How do I track pemvidutide on Shotlee?
Log weekly injections with dose (1.2–2.4mg), track weight, and log body composition changes. Shotlee supports DEXA scan data logging so you can monitor fat vs muscle changes over time.